La Jolla, CA, United States of America

Nicholas Lok Yan


Average Co-Inventor Count = 4.0

ph-index = 1


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Nicholas Lok Yan in Amyloidogenic Immunoglobulin Light Chains

Introduction

Nicholas Lok Yan is an accomplished inventor based in La Jolla, CA (US). He has made significant contributions to the field of immunology, particularly in the treatment of immunoglobulin light chain amyloidosis (AL). His innovative approach addresses the challenges faced by patients suffering from this condition.

Latest Patents

Nicholas Lok Yan holds a patent for the "Stabilization of amyloidogenic immunoglobulin light chains." This patent focuses on the unique antibody light chain protein that misfolds and aggregates, leading to organ degeneration in AL patients. The patent presents small molecule compounds of Formula Ia, Formula Ib, and Formula II, which act as kinetic stabilizers of the native dimeric structure of full-length light chains. These compounds have the potential to slow or stop the amyloidogenicity cascade at its origin, offering hope for patients with substantial cardiac involvement who struggle with existing chemotherapy regimens.

Career Highlights

Throughout his career, Nicholas Lok Yan has demonstrated a commitment to advancing medical science. His work has not only contributed to the understanding of amyloidosis but also provided practical solutions for improving patient outcomes. His innovative research has garnered attention in the scientific community, highlighting his role as a leading inventor in this specialized field.

Collaborations

Nicholas Lok Yan has collaborated with notable researchers, including Jeffery W Kelly and Gareth Morgan. These partnerships have enhanced the development of his patented compounds and have contributed to the broader understanding of amyloidogenic processes.

Conclusion

Nicholas Lok Yan's contributions to the field of immunology, particularly through his patent on the stabilization of amyloidogenic immunoglobulin light chains, represent a significant advancement in the treatment of AL. His innovative work continues to inspire further research and development in this critical area of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…